EX-99.2 3 a2021q3exhibit992.htm EX-99.2 Document

Exhibit 99.2


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$11,963  11,086  7.9 % 7.9 — 
Europe 5,587  4,819 15.9  14.6  1.3
Western Hemisphere excluding U.S. 1,500  1,296  15.7  13.4  2.3
Asia-Pacific, Africa 4,288  3,881  10.5  8.5  2.0
International 11,375  9,996  13.8  12.1  1.7
      
Worldwide$23,338  21,082  10.7 % 9.9  0.8
        
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.






Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
Percent Change
20212020TotalOperationsCurrency
Sales to customers by
geographic area
U.S.$34,993  31,324  11.7 % 11.7 — 
Europe 16,669  13,709  21.6  15.3  6.3
Western Hemisphere excluding U.S. 4,291  3,931  9.2  8.1  1.1
Asia-Pacific, Africa 13,018  11,145  16.8  12.3  4.5
International 33,978  28,785  18.0  13.1  4.9
      
Worldwide$68,971  60,109  14.7 % 12.4  2.3
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
THIRD QUARTER
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$1,625 1,556 4.5 %4.5 — 
    International2,075 1,958 5.9 3.7 2.2 
3,700    3,514 5.3 4.1 1.2 
Pharmaceutical
    U.S.7,221 6,438 12.2 12.2— 
    International5,773 4,980 15.9 14.61.3 
12,994    11,418 13.8 13.20.6 
Medical Devices
    U.S.3,117    3,092 0.8 0.8 — 
    International3,527 3,058 15.4 13.3 2.1 
 6,644    6,150 8.0 7.0 1.0 
U.S.11,963 11,086 7.9 7.9 — 
International11,375 9,996 13.8 12.1 1.7 
Worldwide$23,338 21,082 10.7 %9.9 0.8 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
NINE MONTHS
 Percent Change
20212020TotalOperationsCurrency
Sales to customers by
segment of business
Consumer Health
    U.S.$4,987 4,853 2.8 %2.8 — 
    International5,991 5,582 7.3 3.5 3.8 
10,978    10,435 5.2 3.1 2.1 
Pharmaceutical
    U.S.20,536 18,619 10.3 10.3— 
    International17,256 14,685 17.5 12.55.0 
37,792    33,304 13.5 11.32.2 
Medical Devices
    U.S.9,470    7,852 20.6 20.6 — 
    International10,731 8,518 26.0 20.5 5.5 
 20,201    16,370 23.4 20.5 2.9 
U.S.34,993 31,324 11.7 11.7 — 
International33,978 28,785 18.0 13.1 4.9 
Worldwide$68,971 60,109 14.7 %12.4 2.3 
   
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
THIRD QUARTER
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$23,338 100.0$21,082 100.010.7 
Cost of products sold7,250 31.16,972 33.14.0
Gross Profit16,088 68.914,110 66.914.0 
Selling, marketing and administrative expenses6,000 25.75,431 25.810.5 
Research and development expense3,422 14.72,840 13.520.5 
In-process research and development9003.9138 0.6 
Interest (income) expense, net7 0.0 32 0.1 
Other (income) expense, net1,850 7.9 1,200 5.7  
Restructuring60 0.268 0.3 
Earnings before provision for taxes on income3,849 16.54,401 20.9(12.5)
Provision for taxes on income182 0.8847 4 (78.5)
Net earnings$3,667 15.7$3,554 16.93.2 
Net earnings per share (Diluted)$1.37 $1.33 3.0 
Average shares outstanding (Diluted)2,674.9 2,669.3 
Effective tax rate4.7 %19.2 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$8,058 34.5$7,246 34.411.2 
Net earnings$6,968 29.9$5,868 27.818.7 
Net earnings per share (Diluted)$2.60 $2.20 18.2 
Effective tax rate13.5 %19.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.




Johnson & Johnson and Subsidiaries 
Condensed Consolidated Statement of Earnings  
(Unaudited; in Millions Except Per Share Figures)
NINE MONTHS
20212020Percent
PercentPercentIncrease
Amountto SalesAmountto Sales(Decrease)
Sales to customers$68,971 100.0$60,109 100.014.7 
Cost of products sold21,900 31.820,613 34.36.2
Gross Profit47,071 68.239,496 65.719.2 
Selling, marketing and administrative expenses17,505 25.415,627 26.012.0 
Research and development expense9,994 14.58,127 13.523.0 
In-process research and development9001.3144 0.3  
Interest (income) expense, net83 0.116 0.0  
Other (income) expense, net480 0.7 545 0.9  
Restructuring169 0.2187 0.3 
Earnings before provision for taxes on income17,940 26.014,850 24.720.8 
Provision for taxes on income1,798 2.61,874 3.1 (4.1)
Net earnings$16,142 23.4$12,976 21.624.4 
Net earnings per share (Diluted)$6.04 $4.86 24.3 
Average shares outstanding (Diluted)2,674.6 2,670.8 
Effective tax rate10.0 %12.6 %
Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income$24,125 35.0$19,827 33.021.7 
Net earnings$20,517 29.7$16,468 27.424.6 
Net earnings per share (Diluted)$7.67 $6.17 24.3 
Effective tax rate15.0 %16.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.








Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Third Quarter
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$3,667$3,554
Pre-tax Adjustments
Intangible Asset Amortization expense1,159 1,181
Litigation expense, net2,077 1,477
IPR&D 900  138
Restructuring related121 130
Acquisition, integration and divestiture related 20 (154)
(Gains)/losses on securities (127)32
Medical Device Regulation 59  38
Other - 3
Tax Adjustments
Tax impact on special item adjustments 1
(849)(482)
Tax legislation and related impacts (59) (49)
Adjusted Net Earnings, after tax$6,968$5,868
Average shares outstanding (Diluted)2,674.9 2,669.3
Adjusted net earnings per share (Diluted)$2.60$2.20
Operational adjusted net earnings per share (Diluted)$2.56 
Notes:
1
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.




Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Nine Months Ended
(Dollars in Millions Except Per Share Data)20212020
Net Earnings, after tax- as reported$16,142$12,976
Pre-tax Adjustments
Intangible Asset Amortization expense3,576 3,426
Litigation expense, net2,054 2,210
IPR&D 900 144
Restructuring related333 363
Acquisition, integration and divestiture related 1
(504)(1,087)
(Gains)/losses on securities(335)(174)
Medical Device Regulation161  89
Other -  6
Tax Adjustments
Tax impact on special item adjustments 2
(1,097)(1,002)
Tax legislation and related impacts(713) (483)
Adjusted Net Earnings, after tax$20,517$16,468
Average shares outstanding (Diluted)2,674.6 2,670.8
Adjusted net earnings per share (Diluted)$7.67$6.17
Operational adjusted net earnings per share (Diluted)$7.47 
Notes:
1
Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to the timing of certain developmental milestones associated with the Auris Health acquisition.
2
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.







Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
 THIRD QUARTER 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 5.3 %13.8 %8.0 %10.7 %
 U.S. 4.5 %12.2 %0.8 %7.9 %
 International 5.9 %15.9 %15.4 %13.8 %
 WW Currency 1.20.61.00.8
 U.S. ————
 International 2.21.32.11.7
 WW Operational 4.1 %13.2 %7.0 %9.9 %
 U.S. 4.5 %12.2 %0.8 %7.9 %
 International 3.7 %14.6 %13.3 %12.1 %
General Surgery
Advanced Sterilization Products0.40.1
 U.S. 0.00.0
 International 0.80.2
Skin Health / Beauty
Dr. Ci Labo - Sedona1.10.2
 U.S. 0.00.0
 International 2.00.4
All Other Acquisitions and Divestitures0.50.60.20.4
 U.S. 0.60.00.30.1
 International 0.31.40.00.8
WW Adjusted Operational5.7 %13.8 %7.6 %10.6 %
 U.S. 5.1 %12.2 %1.1 %8.0 %
 International 6.1 %16.0 %14.1 %13.5 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Adjusted Operational Sales Growth (A)
NINE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
 Segments
Consumer Health Pharmaceutical  Medical Devices  Total
 WW As Reported 5.2 %13.5 %23.4 %14.7 %
 U.S. 2.8 %10.3 %20.6 %11.7 %
 International 7.3 %17.5 %26.0 %18.0 %
 WW Currency 2.12.22.92.3
 U.S. ————
 International 3.85.05.54.9
 WW Operational 3.1 %11.3 %20.5 %12.4 %
 U.S. 2.8 %10.3 %20.6 %11.7 %
 International 3.5 %12.5 %20.5 %13.1 %
General Surgery
Advanced Sterilization Products0.60.2
 U.S. 0.00.0
 International 1.20.3
Skin Health / Beauty
Dr. Ci Labo - Sedona0.50.1
U.S.0.00.0
International0.90.2
All Other Acquisitions and Divestitures0.50.50.20.4
 U.S. 0.5(0.1)0.40.1
 International 0.31.30.00.7
WW Adjusted Operational4.1 %11.8 %21.4 %13.1 %
 U.S. 3.3 %10.2 %21.0 %11.8 %
 International 4.7 %13.8 %21.7 %14.4 %
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$68660114.0 %14.0 %— %
Intl68654126.9 22.8 4.1 
WW1,3721,14220.1 18.2 1.9 
SKIN HEALTH / BEAUTY
US569572(0.5)(0.5)— 
Intl555577(3.8)(5.5)1.7 
WW1,124 1,149(2.2)(3.0)0.8 
ORAL CARE
US150164(8.4)(8.4)— 
Intl2482480.1 (1.8)1.9 
WW398 412 (3.3)(4.5)1.2 
BABY CARE
US95915.2 5.2 — 
Intl296302(2.0)(3.1)1.1 
WW391 393 (0.3)(1.2)0.9 
WOMEN'S HEALTH
US3320.1 20.1 — 
Intl2292270.5 0.6 (0.1)
WW2322300.8 0.8 0.0 
WOUND CARE / OTHER
US122125(2.6)(2.6)— 
Intl6164(5.2)(9.0)3.8 
WW182189(3.5)(4.8)1.3 
TOTAL CONSUMER HEALTH
US1,625 1,556 4.5 4.5 — 
Intl2,075 1,958 5.9 3.7 2.2 
WW$3,700 3,514 5.3 %4.1 %1.2 %
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$2,7712,5588.3 %8.3 %— %
Intl1,4801,23020.3 18.8 1.5 
WW4,2503,78912.2 11.7 0.5 
     REMICADE
     US480634(24.3)(24.3)— 
     US Exports (4)
4778(40.2)(40.2)— 
     Intl23420912.2 8.1 4.1 
     WW761921(17.4)(18.3)0.9 
     SIMPONI / SIMPONI ARIA
     US295312(5.3)(5.3)— 
     Intl276280(1.1)(0.7)(0.4)
     WW571592(3.3)(3.1)(0.2)
     STELARA
     US1,5691,31319.5 19.5 — 
     Intl80963427.7 26.3 1.4 
     WW2,3781,94722.2 21.7 0.5 
     TREMFYA
     US376 222 69.7 69.7 — 
     Intl161 105 52.5 50.5 2.0 
     WW537 327 64.1 63.5 0.6 
     OTHER IMMUNOLOGY
     US3 — **— 
     Intl0 3 ***
     WW3 3 (26.4)(27.5)1.1
INFECTIOUS DISEASES
US67941364.3 64.3 — 
Intl70945157.2 55.6 1.6 
WW1,38986460.6 59.8 0.8 
     COVID-19 VACCINE
     US270—**— 
     Intl233—**— 
     WW502—**— 
     EDURANT / rilpivirine
     US12 11 8.4 8.4 — 
     Intl247 226 9.7 8.7 1.0 
     WW259 236 9.6 8.6 1.0 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US3803790.4 0.4 — 
     Intl137147(7.1)(8.8)1.7 
     WW517526(1.7)(2.2)0.5 
     OTHER INFECTIOUS DISEASES
     US1824(26.0)(26.0)— 
     Intl937818.3 15.2 3.1 
     WW1101027.8 5.4 2.4 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$83575910.2 %10.2%—%
Intl8548460.8(0.5)1.3
WW1,6891,6055.34.60.7
     CONCERTA / methylphenidate
     US3543(19.5)(19.5)—
     Intl12210714.212.51.7
     WW1571494.53.31.2
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US64858511.011.0—
     Intl355341 4.33.21.1
     WW1,0049268.58.10.4
     RISPERDAL CONSTA
     US71701.31.3—
     Intl6981(16.7)(16.0)(0.7)
     WW140152(8.4)(8.0)(0.4)
     OTHER NEUROSCIENCE
     US816034.734.7—
     Intl307317(2.9)(4.8)1.9
     WW3883773.11.51.6
ONCOLOGY
US1,5251,26720.320.3—
Intl2,140 1,862 14.913.81.1
WW3,6653,12917.116.50.6
     DARZALEX
     US841 585 43.743.7—
     Intl739 514 43.742.01.7
     WW1,580 1,099 43.742.90.8
     ERLEADA
     US214 152 40.540.5—
     Intl130 55 ***
     WW344 206 66.765.80.9
     IMBRUVICA
     US413 450 (8.3)(8.3)—
     Intl654 581 12.610.91.7
     WW1,066 1,031 3.52.51.0
     ZYTIGA / abiraterone acetate
     US2558 (57.0)(57.0)—
     Intl523532(1.8)(2.1)0.3
     WW548590(7.2)(7.5)0.3
     OTHER ONCOLOGY
     US32 21 49.649.6—
     Intl94181(48.0)(47.2)(0.8)
     WW126203(37.6)(36.9)(0.7)
See footnotes at end of schedule


Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$610 510 19.7 %19.7 %— %
Intl258 239 7.9 8.4 (0.5)
WW868 749 15.9 16.1 (0.2)
     OPSUMIT
     US299 244 22.8 22.8 — 
     Intl159 148 7.4 7.8 (0.4)
     WW458 392 17.0 17.1 (0.1)
     UPTRAVI
     US265 226 17.3 17.3 — 
     Intl44 34 30.4 28.8 1.6 
     WW309 260 19.0 18.8 0.2 
     OTHER PULMONARY HYPERTENSION
     US47 40 14.4 14.4 — 
     Intl54 57 (4.4)(2.1)(2.3)
     WW101 97 3.4 4.8 (1.4)
CARDIOVASCULAR / METABOLISM / OTHER
US800931(14.0)(14.0)— 
Intl333351(5.1)(8.2)3.1 
WW1,1331,281(11.5)(12.4)0.9 
     XARELTO
     US636 630 0.8 0.8 — 
     Intl— — — — — 
     WW636 630 0.8 0.8 — 
     INVOKANA / INVOKAMET
     US66 156 (57.4)(57.4)— 
     Intl67 68 (1.0)(4.3)3.3 
     WW133 224 (40.3)(41.3)1.0 
     PROCRIT / EPREX
     US47 69 (30.9)(30.9)— 
     Intl65 63 3.1 0.5 2.6 
     WW112 132 (14.6)(15.8)1.2 
     OTHER
     US51 75 (32.6)(32.6)— 
     Intl200 219 (8.7)(11.9)3.2 
     WW251 294 (14.8)(17.2)2.4 
TOTAL PHARMACEUTICAL
US7,2216,43812.2 12.2 — 
Intl5,7734,98015.9 14.6 1.3 
WW$12,99411,41813.8 %13.2 %0.6 %
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$444 399 11.1 %11.1 %— %
Intl513 43717.7 15.1 2.6 
WW957 83614.5 13.2 1.3 
ORTHOPAEDICS
US1,249 1,308 (4.5)(4.5)— 
Intl843 774 8.8 6.8 2.0 
WW2,093 2,083 0.5 (0.3)0.8 
     HIPS
     US210 221 (5.3)(5.3)— 
     Intl146 124 18.8 16.0 2.8 
     WW356 345 3.3 2.3 1.0 
     KNEES
     US184 205 (9.8)(9.8)— 
     Intl131 102 28.125.9 2.2 
     WW316 308 2.82.1 0.7 
     TRAUMA
     US455 433 5.3 5.3 — 
     Intl260 253 2.4 0.9 1.5 
     WW715 685 4.2 3.7 0.5 
     SPINE, SPORTS & OTHER
     US400 449 (11.1)(11.1)— 
     Intl306 295 3.5 1.5 2.0 
     WW705 745 (5.3)(6.1)0.8 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
THIRD QUARTER
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$948 913 3.93.9— %
Intl1,457 1,239 17.6 14.8 2.8 
WW2,405 2,152 11.8 10.2 1.6 
     ADVANCED
US440 421 4.6 4.6 — 
Intl705 579 21.8 18.4 3.4 
WW1,144 1,000 14.6 12.6 2.0 
     GENERAL
US508 492 3.33.3— 
Intl752 660 13.9 11.7 2.2 
WW1,261 1,152 9.4 8.1 1.3 
VISION
US475 473 0.6 0.6 — 
Intl714 608 17.4 17.4 0.0 
WW1,189 1,081 10.1 10.0 0.1 
     CONTACT LENSES / OTHER
US359 375 (4.3)(4.3)— 
Intl522 455 14.9 15.2 (0.3)
WW882 830 6.2 6.4 (0.2)
     SURGICAL
US117 98 19.619.6— 
Intl191 153 24.723.7 1.0 
WW308 251 22.722.10.6
TOTAL MEDICAL DEVICES
US3,117 3,092 0.8 0.8 — 
Intl3,527 3,058 15.4 13.3 2.1 
WW$6,644 6,150 8.0 %7.0 %1.0 %
See footnotes at end of schedule







Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US$1,9601,9172.2 %2.2 %— %
Intl1,8941,72210.0 3.9 6.1 
WW3,8543,6395.9 3.0 2.9 
SKIN HEALTH / BEAUTY
US1,8621,7675.4 5.4 — 
Intl1,5951,5065.9 2.1 3.8 
WW3,457 3,2735.6 3.9 1.7 
ORAL CARE
US478510(6.2)(6.2)— 
Intl7626949.9 5.9 4.0 
WW1,240 1,204 3.0 0.8 2.2 
BABY CARE
US2882793.3 3.3 — 
Intl8798315.8 4.6 1.2 
WW1,167 1,110 5.2 4.3 0.9 
WOMEN'S HEALTH
US910(5.7)(5.7)— 
Intl6756543.1 2.3 0.8 
WW6846643.0 2.1 0.9 
WOUND CARE / OTHER
US3903705.3 5.3 — 
Intl1861755.8 0.0 5.8 
WW5755455.4 3.6 1.8 
TOTAL CONSUMER HEALTH
US4,987 4,853 2.8 2.8 — 
Intl5,991 5,582 7.3 3.5 3.8 
WW$10,978 10,435 5.2 %3.1 %2.1 %
See footnotes at end of schedule





Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US$7,9327,3308.2 %8.2 %— %
Intl4,4643,61923.3 17.6 5.7 
WW12,39510,95013.2 11.3 1.9 
     REMICADE
     US1,5081,852(18.6)(18.6)— 
     US Exports (4)
197321(38.7)(38.7)— 
     Intl7216737.1 1.4 5.7 
     WW2,4262,846(14.8)(16.1)1.3 
     SIMPONI / SIMPONI ARIA
     US8408400.0 0.0 — 
     Intl8778276.1 2.8 3.3 
     WW1,7171,6673.0 1.4 1.6 
     STELARA
     US4,3963,66819.9 19.9 — 
     Intl2,4041,79533.9 27.5 6.4 
     WW6,8005,46324.5 22.4 2.1 
     TREMFYA
     US975 650 50.1 50.1 — 
     Intl459 316 45.4 38.0 7.4 
     WW1,434 965 48.5 46.1 2.4 
     OTHER IMMUNOLOGY
     US15 — **— 
     Intl3 9 (68.6)(70.8)2.2 
     WW18 9 91.689.52.1
INFECTIOUS DISEASES
US1,6351,26529.2 29.2 — 
Intl1,7881,39728.0 23.2 4.8 
WW3,4242,66228.6 26.1 2.5 
     COVID-19 VACCINE
     US421—**— 
     Intl346—**— 
     WW766—**— 
     EDURANT / rilpivirine
     US31 33 (4.8)(4.8)— 
     Intl733 684 7.2 1.7 5.5 
     WW764 716 6.7 1.4 5.3 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     US1,1281,154(2.2)(2.2)— 
     Intl440461(4.6)(8.6)4.0 
     WW1,5681,615(2.9)(4.1)1.2 
     OTHER INFECTIOUS DISEASES
     US5579(29.6)(29.6)— 
     Intl2702526.9 2.6 4.3 
     WW325331(1.8)(5.0)3.2 
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
NEUROSCIENCE
US$2,4482,2857.2 %7.2 %— %
Intl2,7702,5658.0 4.1 3.9
WW5,2184,8507.6 5.5 2.1
     CONCERTA / methylphenidate
     US117150(22.1)(22.1)—
     Intl37231916.411.64.8
     WW4894694.10.83.3
     INVEGA SUSTENNA / XEPLION / INVEGA
     TRINZA / TREVICTA
     US1,8821,70410.4 10.4 —
     Intl1,111983 13.0 7.6 5.4
     WW2,9942,68811.4 9.4 2.0
     RISPERDAL CONSTA
     US210220(4.7)(4.7)—
     Intl242254(5.1)(8.3)3.2
     WW452475(4.9)(6.6)1.7
     OTHER NEUROSCIENCE
     US23921013.913.9—
     Intl1,0451,0083.71.52.2
     WW1,2841,2185.53.61.9
ONCOLOGY
US4,3643,62320.420.4—
Intl6,406 5,310 20.615.35.3
WW10,7708,93320.617.43.2
     DARZALEX
     US2,302 1,540 49.549.5—
     Intl2,076 1,397 48.642.26.4
     WW4,378 2,937 49.146.03.1
     ERLEADA
     US578 407 41.841.8—
     Intl329 112 ***
     WW907 519 74.772.22.5
     IMBRUVICA
     US1,311 1,329 (1.3)(1.3)—
     Intl1,996 1,682 18.713.15.6
     WW3,307 3,011 9.96.73.2
     ZYTIGA / abiraterone acetate
     US96 284 (66.2)(66.2)—
     Intl1,6531,5645.70.94.8
     WW1,7491,848(5.4)(9.4)4.0
     OTHER ONCOLOGY
     US76 63 21.021.0—
     Intl352556(36.6)(38.5)1.9
     WW428619(30.7)(32.4)1.7
See footnotes at end of schedule




Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT (2) (3) (Continued)
PULMONARY HYPERTENSION
US$1,778 1,541 15.4 %15.4 %— %
Intl821 742 10.7 7.3 3.4 
WW2,599 2,283 13.9 12.7 1.2 
     OPSUMIT
     US861 729 18.2 18.2 — 
     Intl510 458 11.3 7.7 3.6 
     WW1,371 1,187 15.5 14.1 1.4 
     UPTRAVI
     US792 692 14.6 14.6 — 
     Intl135 100 34.6 27.9 6.7 
     WW927 792 17.1 16.2 0.9 
     OTHER PULMONARY HYPERTENSION
     US125 121 2.8 2.8 — 
     Intl176 183 (3.7)(5.0)1.3 
     WW301 304 (1.1)(1.9)0.8 
CARDIOVASCULAR / METABOLISM / OTHER
US2,3792,574(7.6)(7.6)— 
Intl1,0071,052(4.2)(9.3)5.1 
WW3,3863,625(6.6)(8.1)1.5 
     XARELTO
US1,794 1,716 4.5 4.5 — 
Intl— — — — — 
WW1,794 1,716 4.5 4.5 — 
     INVOKANA / INVOKAMET
US249 405 (38.4)(38.4)— 
Intl194 173 11.9 5.8 6.1 
WW443 578 (23.4)(25.2)1.8 
     PROCRIT / EPREX
US168 215 (21.7)(21.7)— 
Intl198 208 (4.7)(9.7)5.0 
WW366 423 (13.4)(15.8)2.4 
     OTHER
US168 238 (29.3)(29.3)— 
Intl615 670 (8.3)(13.1)4.8 
WW783 908 (13.8)(17.3)3.5 
TOTAL PHARMACEUTICAL
US20,53618,61910.3 10.3 — 
Intl17,25614,68517.5 12.5 5.0 
WW$37,79233,30413.5 %11.3 %2.2 %
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2)
INTERVENTIONAL SOLUTIONS
US$1,353 1,019 32.7 %32.7 %— %
Intl1,5991,13441.1 34.3 6.8 
WW2,9522,15337.1 33.6 3.5 
ORTHOPAEDICS
US3,821 3,427 11.5 11.5 — 
Intl2,611 2,145 21.7 15.4 6.3 
WW6,433 5,572 15.4 13.0 2.4 
     HIPS
     US654 564 15.9 15.9 — 
     Intl451 344 31.3 24.1 7.2 
     WW1,105 908 21.8 19.0 2.8 
     KNEES
     US579 527 10.0 10.0 — 
     Intl403 298 35.4 28.2 7.2 
     WW983 825 19.2 16.6 2.6 
     TRAUMA
     US1,352 1,194 13.3 13.3 — 
     Intl805 698 15.2 9.5 5.7 
     WW2,157 1,892 14.0 11.9 2.1 
     SPINE, SPORTS & OTHER
     US1,236 1,142 8.2 8.2 — 
     Intl952 805 18.2 12.0 6.2 
     WW2,187 1,947 12.3 9.7 2.6 
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
NINE MONTHS
% Change
20212020Reported
Operational (1)
Currency
MEDICAL DEVICES SEGMENT (2) (Continued)
SURGERY
US$2,881 2,247 28.2 %28.2 %— %
Intl4,418 3,556 24.2 18.4 5.8 
WW7,299 5,803 25.8 22.2 3.6 
     ADVANCED
US1,304 1,079 20.9 20.9 — 
Intl2,126 1,644 29.3 23.1 6.2 
WW3,430 2,723 26.0 22.2 3.8 
     GENERAL
US1,577 1,168 35.0 35.0 — 
Intl2,292 1,912 19.9 14.5 5.4 
WW3,869 3,080 25.6 22.3 3.3 
VISION
US1,414 1,160 21.9 21.9 — 
Intl2,103 1,683 25.0 22.0 3.0 
WW3,517 2,843 23.7 22.0 1.7 
     CONTACT LENSES / OTHER
US1,082 924 17.0 17.0 — 
Intl1,525 1,274 19.8 17.3 2.5 
WW2,607 2,198 18.6 17.2 1.4 
     SURGICAL
US333 236 41.1 41.1 — 
Intl577 409 41.1 36.7 4.4 
WW910 645 41.1 38.3 2.8 
TOTAL MEDICAL DEVICES
US9,470 7,852 20.6 20.6 — 
Intl10,731 8,518 26.0 20.5 5.5 
WW$20,201 16,370 23.4 %20.5 %2.9 %
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales